Tigecycline Containing Polymethylmethacrylate Cement Against MRSA, VRE, and ESBL—In Vitro Mechanical and Microbiological Investigations
Michael Abramowicz, Andrej Trampuz, Klaus-Dieter Kühn, Bernd Fink, Steffen Ruchholtz · 2024
Read Tigecycline Containing Polymethylmethacrylate Cement Against MRSA, VRE, and ESBL—In Vitro Mechanical and Microbiological Investigations by Michael Abramowicz, Andrej Trampuz, Klaus-Dieter Kühn, Bernd Fink, Steffen Ruchholtz (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11591008.txt.
Description
Michael Abramowicz and co-authors test bone cement loaded with the antibiotic tigecycline, in a 2024 study. Cement that carries antibiotics is a standard guard against infection in joint replacement surgery. Tigecycline fights a wide range of germs, including strains that resist vancomycin. The team mixed the drug by hand into standard cement and ran strength and germ tests under formal standards.
Both dose levels, half a gram and one gram, kept the cement within strength rules. The lower dose stayed active against germs for up to seven days. The higher dose worked for four to six weeks. Target germs included MRSA and other hard-to-treat strains named in the study title. The authors say hand-mixing these doses in revision surgery can fight infection without weakening the cement.
Catalog record
| CREATOR | Michael Abramowicz, Andrej Trampuz, Klaus-Dieter Kühn, Bernd Fink, Steffen Ruchholtz |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 40 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |